GENEVA–(BUSINESS WIRE)–Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
Category: Business
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
GENEVA–(BUSINESS WIRE)–Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment…
Europa Eyewear Appoints Megan Molony as Chief Executive Officer
CHICAGO–(BUSINESS WIRE)–Europa, a leading designer and manufacturer of premium independent eyewear, proudly announces the appointment of Megan Molony as its new chief executive officer, effective June 16. Molony will oversee the full Europa platform,…
Alfred E. Mann Charities Gives $12 Million for Cell and Gene Therapy Research at Children’s Hospital Los Angeles
LOS ANGELES–(BUSINESS WIRE)–Alfred E. Mann Charities has made a generous gift of $12 million to establish the Alfred E. Mann Cell and Gene Therapy Research Endowment and the Alfred E. Mann Cell and Gene Therapy Research Fund at Children’s Hospital Lo…
Warby Parker Partners with Google To Develop Intelligent Eyewear
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced a partnership with Google to develop AI-powered glasses intended for all-day wear. The partnershi…
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced positive l…
STAAR Surgical Announces $30 Million Share Repurchase Authorization
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authoriz…
National Vision Announces Settlement of 2025 Convertible Senior Notes
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced the settlement of the remaining $84.8 million aggregate principal amount of 2.5% unsecured convertible senior notes due May …
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
GENEVA–(BUSINESS WIRE)–Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
GENEVA–(BUSINESS WIRE)–Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neu…
GenSight Biologics annonce l’approbation de l’ensemble des résolutions soutenues par le Conseil d’Administration lors de son assemblée générale mixte du 13 mai 2025
PARIS–(BUSINESS WIRE)–Regulatory News: L’Assemblée Générale Mixte des actionnaires de la société GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation…
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
PARIS–(BUSINESS WIRE)–Regulatory News: The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies…
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today…
$7.22 Bn OTC Artificial Tears Market Size, Share Analysis, Growth Trends and Forecasts 2024-2025 & 2033 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “OTC Artificial Tears Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The OTC Artificial Tears market is expected to grow from US$ 4….
Vision Care Market Forecast Report and Company Analysis 2025-2033 Featuring Essilor, J&J, Bausch Health, Novartis, Grand Vision, Carl Zeiss, Valeant Pharma, Paragon Vision Science, and Menicon – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The Vision Care Market is anticipated to rise at a compound annual growt…
Warby Parker Announces First Quarter 2025 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. “Our team deliver…
LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects Treated with Valeda